You are here: Industry Insights > nasal polyps

News List

GSK’s Nucala approved to treat chronic rhinosinusitis with nasal polyps pharmatimes
August 02, 2021
GlaxoSmithKline’s (GSK) interleukin-5 (IL-5) inhibitor has received approval from the US Food and Drug Administration (FDA) for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP).
Novartis Announces FDA Approval of Xolair for Nasal Polyps americanpharmaceuticalreview
December 22, 2020
Novartis announced the US Food and Drug Administration (FDA) has approved the company's supplemental Biologics License Application (sBLA) for Xolair® (omalizumab) for the add-on maintenance treatment of nasal polyps in adult patients 18 years of age ...
FDA set to review GSK’s Nucala for nasal polyps pharmatimes
December 11, 2020
The US Food and Drug Administration (FDA) is set to review GlaxoSmithKline’s (GSK) Nucala, after accepting a regulatory submission seeking approval for its use in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
Roche's Xolair gets US nod for nasal polyps treatment pharmatimes
December 03, 2020
Roche’s asthma med Xolair has scored approval from the US Food and Drug Administration (FDA) for the treatment of nasal polyps in adults.
AZ Fasenra shows benefit in chronic rhinosinusitis with nasal polyps pharmatimes
September 14, 2020
AstraZeneca’s Fasenra (benralizumab) significantly reduced the size of nasal polyps and cut nasal blockage in patients with chronic rhinosinusitis, raising hopes for a new treatment option for this condition.
GSK's Nucala shows promise in nasal polyps pharmatimes
April 07, 2020
GlaxoSmithKline has reported positive late-stage data showing the benefit of its biologic Nucala (mepolizumab) in patients with nasal polyps in patient requiring further surgeries for the condition.
FDA agrees to review Novartis’ sBLA of Xolair to treat nasal polyps pharmaceutical-technology
December 16, 2019
The US Food and Drug Administration (FDA) has agreed to review a supplemental biologics license application (sBLA) submitted by Novartis to seek approval for Xolair (omalizumab) to treat nasal polyps.